Related Experiment Video
Updated: Aug 8, 2026
Rapid Homogeneous Detection of Biological Assays Using Magnetic Modulation Biosensing System
Published on: June 14, 2010
A biologic assay for IL-4. Rapid fluorescence assay for IL-4 detection in supernatants and serum
1Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20892.
Insights
A new particle fluorescence immunoassay can detect Interleukin-4 (IL-4) in serum and supernatants. This rapid assay is specific for IL-4 and useful for monitoring IL-4 therapy in cancer patients.
Area of Science:
- Immunology
- Biochemistry
- Cell Biology
Background:
- Interleukin-4 (IL-4) is a key lymphokine produced by T helper cells, influencing various immune cells.
- Conventional IL-4 quantification methods using B cell assays are limited by sensitivity to other cytokines and the need for fresh cells.
- High-throughput analysis requirements necessitate a more efficient IL-4 detection method.
Purpose of the Study:
- To develop and validate a rapid fluorescence immunoassay for Interleukin-4 (IL-4) detection.
- To assess the specificity and sensitivity of the developed assay for IL-4 in biological samples.
- To evaluate the utility of the assay for monitoring IL-4 pharmacokinetics in cancer patients.
Main Methods:
- Development of a particle fluorescence immunoassay utilizing Ramos B cells and anti-IgM antibody to detect IL-4-induced CD23 expression.
- Evaluation of assay sensitivity, with a limit of detection of 6 U in supernatants and serum.
- Assessment of assay specificity against a panel of recombinant cytokines (IL-1, IL-2, IL-3, IL-6, interferons, TNF, GM-CSF).
Main Results:
- The developed particle fluorescence immunoassay reproducibly detects IL-4 down to 6 U in supernatants and serum.
- The assay demonstrates high specificity for IL-4, showing no cross-reactivity with other tested recombinant cytokines.
- In cancer patients receiving IL-4, serum detection revealed a rapid distribution phase (approx. 8 min) and a clearance phase (approx. 48 min).
Conclusions:
- A rapid, specific, and sensitive particle fluorescence immunoassay for IL-4 detection has been successfully developed.
- This assay overcomes limitations of conventional methods and is suitable for high-throughput sample analysis.
- The assay is valuable for monitoring IL-4 levels in serum, particularly for pharmacokinetic studies in patients undergoing IL-4 therapy.
Abstract:
Interleukin-4 (IL-4) is a lymphokine produced by activated T helper cells with effects on T cells, B cells, monocytes and mast cells. The conventional tonsillar B cell assay used for quantification of IL-4 activity is sensitive to the presence of other cytokines and requires the acquisition of fresh cells on a regular basis. We have evaluated the ability of IL-4 in the presence of antibody to IgM to induce CD23 on a cultured B cell line (Ramos) The requirements of measuring hundreds of samples at a single time precluded ready use of a conventional flow cytometer. We therefore developed a rapid fluorescence assay which allows the detection of IL-4 in supernatants and serum. The use of a particle fluorescence immunoassay reproducibly allows detection of IL-4 to 6 U in supernatants and serum. This assay is specific for IL-4 and is not sensitive to other recombinant cytokines including IL-1, IL-2, IL-3, IL-6; interferon-alpha, -beta or -gamma, tumor necrosis factor (TNF) or GM-CSF. Finally, in cancer patients receiving IL-4 its detection in serum using this assay reveals an alpha distribution phase of approximately 8 min and a beta clearance phase of approximately 48 min.
